MX2009013683A - Materiales y metodos para el tratamiento y diagnostico de trastornos asociados con estres oxidativo. - Google Patents

Materiales y metodos para el tratamiento y diagnostico de trastornos asociados con estres oxidativo.

Info

Publication number
MX2009013683A
MX2009013683A MX2009013683A MX2009013683A MX2009013683A MX 2009013683 A MX2009013683 A MX 2009013683A MX 2009013683 A MX2009013683 A MX 2009013683A MX 2009013683 A MX2009013683 A MX 2009013683A MX 2009013683 A MX2009013683 A MX 2009013683A
Authority
MX
Mexico
Prior art keywords
lipoic acid
methods
compositions
subject invention
administration
Prior art date
Application number
MX2009013683A
Other languages
English (en)
Spanish (es)
Inventor
Jay Pravda
Original Assignee
Jay Pravda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jay Pravda filed Critical Jay Pravda
Publication of MX2009013683A publication Critical patent/MX2009013683A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Dental Preparations (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
MX2009013683A 2007-06-13 2008-06-13 Materiales y metodos para el tratamiento y diagnostico de trastornos asociados con estres oxidativo. MX2009013683A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93450507P 2007-06-13 2007-06-13
US6374508P 2008-02-06 2008-02-06
PCT/US2008/007401 WO2008156671A2 (en) 2007-06-13 2008-06-13 Materials and methods for treatment and diagnosis of disorders associated with oxidative stress

Publications (1)

Publication Number Publication Date
MX2009013683A true MX2009013683A (es) 2010-04-07

Family

ID=40156844

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013683A MX2009013683A (es) 2007-06-13 2008-06-13 Materiales y metodos para el tratamiento y diagnostico de trastornos asociados con estres oxidativo.

Country Status (14)

Country Link
US (2) US8476233B2 (enExample)
EP (2) EP2392321A1 (enExample)
JP (1) JP2010529197A (enExample)
KR (1) KR20100038098A (enExample)
CN (1) CN101707877B (enExample)
AT (1) ATE529105T1 (enExample)
AU (1) AU2008266996A1 (enExample)
BR (1) BRPI0812729A2 (enExample)
CA (1) CA2691132C (enExample)
IL (1) IL202685A0 (enExample)
MX (1) MX2009013683A (enExample)
NZ (1) NZ581710A (enExample)
WO (1) WO2008156671A2 (enExample)
ZA (1) ZA200908828B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100112088A1 (en) * 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
RU2649807C2 (ru) * 2012-02-13 2018-04-04 Космо Текнолоджиз Лимитед Способ лечения заболеваний кишечника с присутствием по меньшей мере одного воспалительного компонента
EP2822542A1 (en) * 2012-03-07 2015-01-14 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
EP2866565A4 (en) * 2012-07-03 2016-04-13 Jay Pravda METHOD FOR TREATING, DIAGNOSIS AND / OR MONITORING THE PROGRESSION OF OXO ASSOCIATED STATES
EP2916818B1 (en) 2012-11-09 2017-02-01 Scidose LLC Enema composition for treatment of ulcerative colitis having long term stability
CN103622974B (zh) * 2013-12-05 2016-04-20 武汉武药科技有限公司 一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法
CN107249595A (zh) 2015-01-26 2017-10-13 Ea制药株式会社 灌肠剂
PT3115037T (pt) * 2015-07-08 2018-10-22 Dr Falk Pharma Gmbh Formulação farmacêutica para o tratamento de alterações inflamatórias do reto
WO2017091072A1 (en) * 2015-11-27 2017-06-01 Birrbeheer B.V. Butyrate salts for use in inflammatory diseases
WO2018053605A1 (en) * 2016-09-26 2018-03-29 Precision Medicine Holdings Pty Ltd Diagnosis, prognosis and treatment for schizophrenia and schizoaffective psychosis
WO2018122086A1 (en) * 2016-12-28 2018-07-05 Dr. Falk Pharma Gmbh Enema for rectal application
CN108034631A (zh) * 2017-12-04 2018-05-15 武汉轻工大学 一种双氧水诱导猪小肠上皮细胞凋亡模型的建立方法
JP2019113375A (ja) * 2017-12-22 2019-07-11 サッポロホールディングス株式会社 腸内環境評価方法、大腸炎罹患リスク評価方法、及び腸内環境改善物質のスクリーニング方法
WO2019142799A1 (ja) * 2018-01-18 2019-07-25 学校法人慶應義塾 潰瘍性大腸炎治療カプセル剤
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
AU2023312830A1 (en) * 2022-07-27 2025-02-20 Redox Bioscience LLC Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome
JP2025066445A (ja) * 2023-10-11 2025-04-23 国立大学法人東北大学 炎症性疾患の治療薬、及び治療薬のスクリーニング方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211777A (en) * 1977-11-25 1980-07-08 Fisons Limited Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
WO1981002671A1 (en) 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
US4657900A (en) 1983-09-27 1987-04-14 Rowell Laboratories Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method
EP0382066A3 (de) 1989-02-09 1992-01-08 ASTA Medica Aktiengesellschaft Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum
GB8909559D0 (en) 1989-04-26 1989-06-14 Smith Kline French Lab Pharmaceutical compositions
US5378470A (en) * 1989-07-25 1995-01-03 Henning Berlin Gmbh Rectally administered pharmaceutical preparation
PT95826B (pt) 1989-11-09 1997-11-28 Asta Medica Ag Processo para a preparacao de composicoes farmaceuticas contendo como ingrediente activo acido r-alfa-liponico ou acido s-alfa-liponico
DE4218572A1 (de) 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
US5569670A (en) 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US8178516B2 (en) 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
JP2917799B2 (ja) 1994-03-11 1999-07-12 田辺製薬株式会社 消化管内適所放出型製剤
US5563131A (en) 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
DE19509806A1 (de) 1995-03-21 1996-09-26 Basf Ag Lagerstabile Arzneiformen
US5817630A (en) 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
US6197749B1 (en) 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
WO1999055326A1 (en) 1998-04-30 1999-11-04 Vit-Immune, L.C. Method of treatment of glutathione deficient mammals
CA2274943A1 (en) * 1998-06-17 1999-12-17 Stephen L. Wolman Compositions for the treatment and prevention of inflammatory diseases of the gastrointestinal tract and methods and uses thereof
AR042572A1 (es) 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
EP1172110A3 (de) 2000-07-07 2003-09-17 Basf Aktiengesellschaft Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
JP2005512946A (ja) 2001-05-09 2005-05-12 ノバルティス アクチエンゲゼルシャフト 選択的免疫調節法
US20030235571A1 (en) 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US7195766B2 (en) 2002-09-10 2007-03-27 National Jewish Medical And Research Center Product and process for liquefaction of mucus or sputum
US7157444B2 (en) 2002-12-21 2007-01-02 Deanna Jean Nelson Aminosalicylate derivatives for treatment of inflammatory bowel disease
DE10305661A1 (de) 2003-02-12 2004-08-26 Degussa Ag Darreichungsform zur Kolon-spezifischen Wirkstofffreisetzung
US20060264408A1 (en) * 2003-03-06 2006-11-23 Haj-Yehia Abdullah I Sod minic multifunctional compounds for treating inflammatory bowel disease
US20100112088A1 (en) 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress

Also Published As

Publication number Publication date
BRPI0812729A2 (pt) 2019-02-12
WO2008156671A3 (en) 2009-03-12
US20100184728A1 (en) 2010-07-22
CN101707877B (zh) 2013-01-09
CA2691132A1 (en) 2008-12-24
JP2010529197A (ja) 2010-08-26
CN101707877A (zh) 2010-05-12
US20130344184A1 (en) 2013-12-26
AU2008266996A1 (en) 2008-12-24
KR20100038098A (ko) 2010-04-12
US8476233B2 (en) 2013-07-02
EP2162125A2 (en) 2010-03-17
ZA200908828B (en) 2010-12-29
IL202685A0 (en) 2010-06-30
CA2691132C (en) 2016-01-12
EP2392321A1 (en) 2011-12-07
EP2162125B1 (en) 2011-10-19
WO2008156671A2 (en) 2008-12-24
ATE529105T1 (de) 2011-11-15
NZ581710A (en) 2012-02-24
EP2162125A4 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
ZA200908828B (en) Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
Schwindling et al. Double-crown–retained removable dental prostheses: A retrospective study of survival and complications
WO2008085484A3 (en) Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
Jokstad et al. Ten years' clinical evaluation of three luting cements
WO2005072113A3 (en) Compositions and methods of treatment for inflammatory diseases
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2008116150A3 (en) Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
GEP20156281B (en) Orally administered corticosteroid compositions
WO2011045415A3 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
Naqvi et al. Curcumin lessens unpredictable chronic mild stress-induced depression and memory deficits by modulating oxidative stress and cholinergic activity
WO2008137762A3 (en) Methods of diagnosis and treatment of crohn's disease
WO2006050479A3 (en) Compositions and methods for diagnosing colon disorders
ZA202002103B (en) Compounds as mpges-1 inhibitors
Kirmeier et al. The supernumerary nasal tooth
Mallineni et al. Talon cusp affecting primary dentition in two siblings: a case report
JP2015523364A5 (enExample)
BRPI0622008A2 (pt) métodos de tratamento para colite ulcerativa
Irina et al. Aspects related to the follow-up of patients with removable prostheses
Scollard Leprosy is (still) here, but recognition is often delayed
WO2018191379A3 (en) CHITINASE DELIVERY IN RESPIRATORY TRACT TO TREAT INFLAMMATORY AND AGE-RELATED LUNG FIBROSIS
Gorovenko et al. Genetic polymorphism of glutathione-s-transferase M1, T1 and susceptibility to premenstrual asthma in Ukrainian population
CRĂCIUN et al. ADVERSE REACTIONS ASSOCIATED WITH DENTAL MATERIALS. A REVIEW.
Czaja Old Age and Steatohepatitis: A Dangerous Liaison?
Mihaylova et al. KIR AND HLA GENETIC BACKGROUND INFLUENCE THE COURSE OF HBV INFECTION
Kuchmin et al. Condition of the intestinal tract microbiocenosis in patients with nonalcoholic fatty liver disease and the methods of its correction

Legal Events

Date Code Title Description
FG Grant or registration